descriptive
Analysis v1
32
0
About half of all patients and over 60% of those with higher initial liver fat saw their liver fat drop by at least 30% after taking saroglitazar for 24 weeks. This finding is from the abstract summary - full study details were not available
Scientific Claim
A 30% relative reduction in liver fat (MRI-PDFF) was observed in 47% of all patients and 63% of patients with baseline MRI-PDFF greater than 5% after saroglitazar treatment.
Original Statement
“A relative 30% reduction from baseline MRI-PDFF value was noted in 47% of all patients and 63% of patients with baseline MRI-PDFF >5%.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract uses 'was noted', which correctly describes the observation without implying causation.
Evidence from Studies
Supporting (1)
32
32
Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients
Cross-Sectional Study
Human
2023 Sep 1Contradicting (0)
0
No contradicting evidence found